Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study
在MMR功能正常的转移性结直肠癌患者中，肝转移并不能预测一线FOLFOXIRI联合贝伐单抗方案加用阿特珠单抗的耐药性：AtezoTRIBE研究的二次分析
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.104135
Antoniotti, C; Carullo, M; Rossini, D; Pietrantonio, F; Salvatore, L; Lonardi, S; Tamberi, S; Sciortino, C; Conca, V; Calegari, M A; Ciracì, P; Tamburini, E; Bergamo, F; Boccaccio, C; Passardi, A; Ritorto, G; Ugolini, C; Aprile, G; Galon, J; Cremolini, C
